Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Hepion Pharmaceuticals, Inc. HEPA

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$-8.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2023 · Revenue 0.0 · Net income -48.9
-20M-40M
20132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2023 · ROE -171.3%
-200%-400%-600%
201320192025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -40.9
-15M-30M
201320192025

Total assetsUSD 3.1M
EquityUSD 2.7M
CashUSD 1.8M
Current ratio10.25×

Equity funds 87% of total assets.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
HEPA, 13-year financial record
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B◌◌0.00.00.00.0◌◌◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌−0.0−0.0−0.0−0.0
Income tax $B◌−0.0−0.0−0.00.00.0−0.0−0.0−0.0−0.0◌0.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌−0.0−0.0−0.0−0.0−0.0◌◌−0.0−0.0−0.0−0.0
EPS, diluted $−0.88−107.35−616.07−11.90−0.47−2.10−6.11−97.35◌−2.41−0.63−1.02−0.41
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————
ROE %——−171.3−59.1−49.0−72.5−81.2−348.2◌−287.0−714.7——
Shares out B0.010.000.000.080.080.030.000.000.010.080.030.020.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 51 reconciliationsAUDITED

Reconciled in 13 of the 13 fiscal years we could check. 12 checks were skipped: the balance sheet is not tagged before 2013. Six checks were skipped: EPS is not tagged before 2013.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image